Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany

NCT02450812 · clinicaltrials.gov ↗

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms, Castration-Resistant

Interventions

DRUG: Radium-223-dichloride (Xofigo, BAY88-8223)

Sponsor

Bayer